Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted ...

30 August 2026 · By · Wire by Fusion42

Published

30 August 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at seekingalpha.com →

◆ Verified

Fusion42 · 31 August 2026 · Fusion42 review

The FDA has approved LISRAYA as the first oral targeted therapy for adult patients with dermatomyositis, a rare inflammatory muscle disease.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 4 sources have reported it between 28 Aug 2026 and 30 Aug 2026.

◆ ◆ The Wire takeaway

Drug developers focused on rare autoimmune diseases now see a clear US regulatory path for oral targeted therapies. You can accelerate pipelines by positioning candidates for faster FDA acceptance in dermatomyositis and related conditions.

◆ Coverage

4 sources · first reported 28 Aug 2026 · latest 30 Aug 2026

◆ Related on Wire

◆ Topics

Drug DiscoveryFDA-approvaloral-therapydermatomyositisrare-diseasedrug-approval